Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Latest twist in uniQure’s tale: possible sale

June 18, 2019 12:47 AM UTC

Five years after returning to the public markets, uniQure may be on the block.

While the Dutch gene therapy play declined to comment on a Bloomberg report citing undisclosed sources that the biotech was exploring options, including a sale or partnerships, investors bid up shares of the rare disease play 12% to finish at its highest-ever close, $81.14, and a market cap of about $3.1 billion...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article